Sosei Heptares

Sosei Heptares is rated 3 out of 5 in the category biotechnology. Read and write reviews about Sosei Heptares. Sosei Heptares is an international biopharmaceutical company focused on the design and development of new medicines originating from its proprietary GPCR-targeted StaR® technology and structure-based drug design platform capabilities. The Company is advancing a broad and deep pipeline of partnered and wholly owned product candidates in multiple therapeutic areas, including CNS, cancer, metabolic diseases and other rare/specialty indications. Our partners and collaborators include AstraZeneca, Allergan, Pfizer, Daiichi-Sankyo, PeptiDream, Kymab, MorphoSys and Novartis. The Company is headquartered in Japan with R&D facilities in the UK. Sosei Heptares is the corporate brand of Sosei Group Corpoation, which is listed on the Tokyo Stock Exchange (ticker: 4565). For more information, please visit www.soseiheptares.com